Methyl 3,3,3-trifluoro-2,2-dimethylpropanoate is a trifluoromethlated pharmaceutical intermediate, for instance, in the preparation of RET Kinase inhibitor as a clinical candidate to treat IBS disease.
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. 
Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS. 
 M.W.Rowbotton, et al, J. Med. Chem., 2015, 55(3), pp 1082-1105.